Tenon MedicalTNON
TNON
About: Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
Employees: 27
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
98% more capital invested
Capital invested by funds: $163K [Q4 2024] → $322K (+$159K) [Q1 2025]
17% more funds holding
Funds holding: 12 [Q4 2024] → 14 (+2) [Q1 2025]
0.3% less ownership
Funds ownership: 2.76% [Q4 2024] → 2.46% (-0.3%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3
241%
upside
Avg. target
$3
241%
upside
High target
$3
241%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Alliance Global Partners Scott Henry | 241%upside $3 | Buy Initiated | 9 Apr 2025 |
Financial journalist opinion
Neutral
Accesswire
4 days ago
Tenon Medical Announces Initial Case Series Utilizing Catamaran(R) SI Joint Fusion System to Enhance Stabilization of the SI Joint for Patients Undergoing Lumbar Fusion
~ Andrew J. Trontis, MD from Progressive Spine and Orthopaedics, (Englewood, NJ) Completes Initial Case Series ~ LOS GATOS, CA / ACCESS Newswire / June 12, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the completion of an initial case series utilizing the Catamaran® SI Joint Fusion System (the "Catamaran") to immobilize & stabilize the SI Joint providing added support at the base of a lumbar or thoracolumbar fusion.
Neutral
Seeking Alpha
1 month ago
Tenon Medical, Inc. (TNON) Q1 2025 Earnings Call Transcript
Tenon Medical, Inc. (NASDAQ:TNON ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Steve Foster - President & Chief Executive Officer Kevin Williamson - Chief Financial Officer Conference Call Participants Scott Henry - Alliance Global Partners Nicholas Sherwood - Maxim Group Operator Greetings. And welcome to the Tenon Medical First Quarter 2025 Financial Results and Corporate Update Conference Call.
Neutral
Accesswire
1 month ago
Tenon Medical Reports First Quarter 2025 Financial Results
~ FDA Clearance of Catamaran® SI Joint Fusion System for New Indication to Augment Spinal Fusion ~ ~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and International Patents ~ ~ Received Gross Proceeds of ~$7.0 Million from Equity Financing Transactions ~ ~ National Commercial Launch of Catamaran SE in Mid-2025 ~ LOS GATOS, CA / ACCESS Newswire / May 13, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today reported financial results for the first quarter ended March 31, 2025. Financial Results and Business Updates First Quarter 2025 Results: Revenue of $0.7 million, in line with the first quarter of 2024.
Neutral
Accesswire
1 month ago
Tenon Medical, Inc. Announces Timing of First Quarter 2025 Financial Results
LOS GATOS, CA / ACCESS Newswire / April 29, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the first quarter 2025 ended March 31, 2025 after market close on Tuesday, May 13, 2025. The Company will also hold a conference call on the same day at 4:30 p.m.
Neutral
Accesswire
2 months ago
Tenon Medical, Inc. Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the issuance and sale of 1,271,500 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $2.00. In a concurrent private placement (the "Private Placement" and together with the registered offering, the "Offerings"), the Company also agreed to issue to the same investor warrants to purchase up to 1,271,500 shares of its common stock (the "Common Warrants").
Neutral
Accesswire
2 months ago
Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the issuance and sale of 733,500 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $2.00. In a concurrent private placement (the "Private Placement" and together with the registered offering, the "Offerings"), the Company also agreed to issue to the same investor warrants to purchase up to 733,500 shares of its common stock (the "Common Warrants").
Neutral
Accesswire
2 months ago
Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion
~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, announced today that the U.S. Food and Drug Administration (FDA) has provided clearance of an expanded indication for the Catamaran® SI Joint Fusion System (the "Catamaran") for use in augmenting thoracolumbar fusion. With this approval, the Catamaran is now indicated to treat the SI joint as either a stand-alone treatment or to augment a spinal fusion.
Neutral
Seeking Alpha
2 months ago
Tenon Medical, Inc. (TNON) Q4 2024 Earnings Call Transcript
Tenon Medical, Inc. (NASDAQ:TNON ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Steve Foster - President and CEO Kevin Williamson - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings. And welcome to the Tenon Medical Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
Neutral
Accesswire
2 months ago
Tenon Medical Reports Fourth Quarter and Full Year 2024 Financial Results
~ Full Year 2024 Revenue of $3.3 Million, a 12% Increase Compared to Prior Year ~ ~ Interim Analysis from MAINSAIL Study Reinforces Safety Profile, Effectiveness and Confirmation of Fusion ~ ~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and International Patents ~ ~ Introduced Catamaran SE Platform and Successfully Completed Initial Clinical Procedures ~ ~ National Commercial Launch of Catamaran SE in Mid-2025 ~ LOS GATOS, CA / ACCESS Newswire / March 20, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today reported financial results for the fourth quarter and year ended December 31, 2024. Financial Results and Business Updates Fourth Quarter 2024 Results: Revenue of $0.8 million, in line with the fourth quarter of 2023.
Neutral
Accesswire
3 months ago
Tenon Medical, Inc. Announces a Warrant Inducement Transaction for $3.0 Million in Gross Proceeds
LOS GATOS, CA / ACCESS Newswire / March 11, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of Series A Warrants to purchase up to 1,222,850 shares of common stock (the "Series A Warrants") and Series B Warrants to purchase up to 1,222,850 shares of common stock (the "Series B Warrants", and together with the Series A Warrants the "Existing Warrants") at a reduced exercise price of $1.25 for gross cash proceeds of approximately $3.0 million, before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
Charts implemented using Lightweight Charts™